{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T21:16:25Z","timestamp":1793222185783,"version":"4.5.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2018,5,31]],"date-time":"2018-05-31T00:00:00Z","timestamp":1527724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Lessons Learned<\/jats:title><jats:p>Ramucirumab plus pembrolizumab revealed no unexpected safety findings in patients with advanced or metastatic biliary tract cancer, which is consistent with reports of other tumor cohorts within this phase Ia\/b trial. Ramucirumab plus pembrolizumab did not demonstrate an improvement in overall survival when compared with historical controls in biomarker unselected, heavily pretreated patients with advanced or metastatic biliary tract cancer. Patients with programmed death-ligand 1 (PD-L1)-positive tumors had improved overall survival compared with patients with PD-L1-negative disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Background<\/jats:title><jats:p>Few treatment options exist for patients with advanced biliary tract cancer (BTC) following progression on gemcitabine-cisplatin. Preclinical evidence suggests that simultaneous blockade of vascular endothelial growth factor receptor 2 (VEGFR-2) and programmed death 1 (PD-1) or programmed death-ligand 1 (PD-L1) enhances antitumor effects. We assessed the safety and efficacy of ramucirumab, an IgG1 VEGFR-2 antagonist, with pembrolizumab, an IgG4 PD-1 antagonist, in biomarker-unselected patients with previously treated advanced or metastatic BTC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients had previously treated advanced or metastatic adenocarcinoma of the gallbladder, intrahepatic and extrahepatic bile ducts, or ampulla of Vater. Ramucirumab 8 mg\/kg was administered intravenously on days 1 and 8 with intravenous pembrolizumab 200 mg on day 1 every 3 weeks. The primary endpoint was safety and tolerability of the combination. Secondary endpoints included objective response rate (ORR), progression-free survival (PFS), and overall survival (OS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty-six patients were treated at 12 centers in five countries. Hypertension was the most common grade 3 treatment-related adverse event (TRAE), occurring in five patients. One patient experienced a grade 4 TRAE (neutropenia), and no treatment-related deaths occurred. Objective response rate was 4%. Median progression-free survival and overall survival were 1.6 months and 6.4 months, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Ramucirumab-pembrolizumab showed limited clinical activity with infrequent grade 3\u20134 TRAEs in patients with biomarker-unselected progressive BTC.<\/jats:p><\/jats:sec>","DOI":"10.1634\/theoncologist.2018-0044","type":"journal-article","created":{"date-parts":[[2018,5,31]],"date-time":"2018-05-31T15:41:25Z","timestamp":1527781285000},"page":"1407-e136","source":"Crossref","is-referenced-by-count":139,"title":["Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF)"],"prefix":"10.1093","volume":"23","author":[{"given":"Hendrik-Tobias","family":"Arkenau","sequence":"first","affiliation":[{"name":"Drug Development Unit, Sarah Cannon Research Institute UK, London, United Kingdom"},{"name":"Cancer Institute, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Martin-Liberal","sequence":"additional","affiliation":[{"name":"Vall d'Hebron Institute of Oncology, Barcelona, Spain"},{"name":"Catalan Institute of Oncology (ICO), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiliano","family":"Calvo","sequence":"additional","affiliation":[{"name":"Early Clinical Drug Development Program, START Madrid-HM CIOCC, Centro Integral Oncol\u00f3gico Clara Campal, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Penel","sequence":"additional","affiliation":[{"name":"Centre Oscar Lambret, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew G.","family":"Krebs","sequence":"additional","affiliation":[{"name":"The Christie NHS Foundation Trust and The University of Manchester, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy S.","family":"Herbst","sequence":"additional","affiliation":[{"name":"Yale University School of Medicine, Yale Cancer Center, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Walgren","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan C.","family":"Widau","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gu","family":"Mi","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Jin","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ferry","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Chau","sequence":"additional","affiliation":[{"name":"Royal Marsden Hospital, Sutton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,5,31]]},"reference":[{"key":"2021122511252971900_onco12611-bib-0001","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/nri3064","article-title":"The parallel lives of angiogenesis and immunosuppression: Cancer and other tales","volume":"11","author":"Motz","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"2021122511252971900_onco12611-bib-0002","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1182\/blood-2007-01-065714","article-title":"Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF","volume":"110","author":"Huang","year":"2007","journal-title":"Blood"},{"key":"2021122511252971900_onco12611-bib-0003"},{"key":"2021122511252971900_onco12611-bib-0004","doi-asserted-by":"crossref","first-page":"e14589","DOI":"10.1200\/JCO.2017.35.15_suppl.e14589","article-title":"Development of the combined positive score (CPS) for the evaluation of PD-L1 in solid tumors with the immunohistochemistry assay PD-L1 IHC 22C3 pharmDx","volume":"35","author":"Kulangara","year":"2017","journal-title":"J Clin Oncol"},{"key":"2021122511252971900_onco12611-bib-0005","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1001\/jamaoncol.2015.0735","article-title":"The global burden of cancer 2013","volume":"1","author":"Global Burden of Disease Cancer Collaboration","year":"2015","journal-title":"JAMA Oncol"},{"key":"2021122511252971900_onco12611-bib-0006","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1634\/theoncologist.2015-0446","article-title":"Forty-year trends in cholangiocarcinoma incidence in the U.S.: Intrahepatic disease on the rise","volume":"21","author":"Saha","year":"2016","journal-title":"The Oncologist"},{"key":"2021122511252971900_onco12611-bib-0007","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/S0140-6736(13)61903-0","article-title":"Cholangiocarcinoma","volume":"383","author":"Razumilava","year":"2014","journal-title":"Lancet"},{"key":"2021122511252971900_onco12611-bib-0008","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/hep.24145","article-title":"Development of molecularly targeted therapies in biliary tract cancers: Reassessing the challenges and opportunities","volume":"53","author":"Zhu","year":"2011","journal-title":"Hepatology"},{"key":"2021122511252971900_onco12611-bib-0009","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/sj.bjc.6605779","article-title":"Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: A comparative multicentre study in Japan","volume":"103","author":"Okusaka","year":"2010","journal-title":"Br J Cancer"},{"key":"2021122511252971900_onco12611-bib-0010","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"2021122511252971900_onco12611-bib-0011","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1093\/annonc\/mdu162","article-title":"Second-line chemotherapy in advanced biliary cancer: A systematic review","volume":"25","author":"Lamarca","year":"2014","journal-title":"Ann Oncol"},{"key":"2021122511252971900_onco12611-bib-0012","doi-asserted-by":"crossref","first-page":"6674","DOI":"10.1158\/1078-0432.CCR-07-5212","article-title":"Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients","volume":"14","author":"Finke","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2021122511252971900_onco12611-bib-0013","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nm.3541","article-title":"Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors","volume":"20","author":"Motz","year":"2014","journal-title":"Nat Med"},{"key":"2021122511252971900_onco12611-bib-0014","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1158\/0008-5472.CAN-12-2325","article-title":"VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer","volume":"73","author":"Terme","year":"2013","journal-title":"Cancer Res"},{"key":"2021122511252971900_onco12611-bib-0015","doi-asserted-by":"crossref","first-page":"12624","DOI":"10.1038\/ncomms12624","article-title":"Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma","volume":"7","author":"Wallin","year":"2016","journal-title":"Nat Commun"},{"key":"2021122511252971900_onco12611-bib-0016","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.ejso.2007.02.020","article-title":"Evaluation of VEGF A expression and microvascular density as prognostic factors in extrahepatic cholangiocarcinoma","volume":"33","author":"Mobius","year":"2007","journal-title":"Eur J Surg Oncol"},{"key":"2021122511252971900_onco12611-bib-0017","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/01.coc.0000204402.29830.08","article-title":"The clinicopathologic significance of the expression of vascular endothelial growth factor-C in intrahepatic cholangiocarcinoma","volume":"29","author":"Park","year":"2006","journal-title":"Am J Clin Oncol"},{"key":"2021122511252971900_onco12611-bib-0018","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.ejso.2003.09.013","article-title":"Vascular endothelial growth factor (VEGF) expression in operable gallbladder carcinomas","volume":"29","author":"Giatromanolaki","year":"2003","journal-title":"Eur J Surg Oncol"},{"key":"2021122511252971900_onco12611-bib-0019","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/sj.bjc.6604129","article-title":"Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma","volume":"98","author":"Yoshikawa","year":"2008","journal-title":"Br J Cancer"},{"key":"2021122511252971900_onco12611-bib-0020","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S1470-2045(15)00139-4","article-title":"Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): A randomised phase 2 trial","volume":"16","author":"Valle","year":"2015","journal-title":"Lancet Oncol"},{"key":"2021122511252971900_onco12611-bib-0021","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(09)70333-X","article-title":"Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: A phase 2 study","volume":"11","author":"Zhu","year":"2010","journal-title":"Lancet Oncol"},{"key":"2021122511252971900_onco12611-bib-0022","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1200\/JCO.2010.28.4075","article-title":"Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: A phase II consortium study","volume":"28","author":"Lubner","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122511252971900_onco12611-bib-0023","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx091.010","article-title":"90PDPreviously treated advanced NSCLC cohort from a multi-disease phase 1 study of ramucirumab (R) plus pembrolizumab (P): Efficacy and safety data","volume":"28","author":"Herbst","year":"2017","journal-title":"Ann Oncol"},{"issue":"suppl 6","key":"2021122511252971900_onco12611-bib-0024","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1200\/JCO.2017.35.6_suppl.349","article-title":"A multicohort phase I study of ramucirumab (R) plus pembrolizumab (P): Interim safety and clinical activity in patients with urothelial carcinoma","volume":"35","author":"Petrylak","year":"2017","journal-title":"J Clin Oncol"},{"issue":"suppl 4","key":"2021122511252971900_onco12611-bib-0025","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1200\/JCO.2017.35.4_suppl.102","article-title":"Interim safety and clinical activity in patients (pts) with advanced gastric or gastroesophageal junction (G\/GEJ) adenocarcinoma from a multicohort phase 1 study of ramucirumab (R) plus pembrolizumab (P)","volume":"35","author":"Chau","year":"2017","journal-title":"J Clin Oncol"},{"key":"2021122511252971900_onco12611-bib-0026","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"2021122511252971900_onco12611-bib-0027","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"2021122511252971900_onco12611-bib-0028","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/jso.21376","article-title":"Interaction of B7-H1 on intrahepatic cholangiocarcinoma cells with PD-1 on tumor-infiltrating T cells as a mechanism of immune evasion","volume":"100","author":"Ye","year":"2009","journal-title":"J Surg Oncol"},{"key":"2021122511252971900_onco12611-bib-0029","doi-asserted-by":"crossref","first-page":"6002","DOI":"10.1158\/1078-0432.CCR-17-0020","article-title":"Clinical development of PD-1\/PD-L1 immunotherapy for gastrointestinal cancers: Facts and hopes","volume":"23","author":"Chau","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2021122511252971900_onco12611-bib-0030","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1016\/S0959-8049(16)30326-4","article-title":"525 Safety and efficacy of pembrolizumab (MK-3475) in patients (pts) with advanced biliary tract cancer: Interim results of KEYNOTE-028","volume":"51","author":"Bang","year":"2015","journal-title":"Eur J Cancer"},{"key":"2021122511252971900_onco12611-bib-0031","doi-asserted-by":"crossref","DOI":"10.1101\/mcs.a001974","article-title":"Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer","volume":"3","author":"Czink","year":"2017","journal-title":"Cold Spring Harb Mol Case Stud"},{"key":"2021122511252971900_onco12611-bib-0032","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"2021122511252971900_onco12611-bib-0033","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122511252971900_onco12611-bib-0034","doi-asserted-by":"crossref","first-page":"62","DOI":"10.21037\/cco.2016.10.04","article-title":"Biliary carcinomas: Pathology and the role of DNA mismatch repair deficiency","volume":"5","author":"Silva","year":"2016","journal-title":"Chin Clin Oncol"},{"key":"2021122511252971900_onco12611-bib-0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00073","article-title":"Landscape of microsatellite instability across 39 cancer types","author":"Bonneville","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"2021122511252971900_onco12611-bib-0036","doi-asserted-by":"crossref","first-page":"712TiP","DOI":"10.1093\/annonc\/mdw371.104","article-title":"Cisplatin and gemcitabine plus ramucirumab or merestinib or placebo in first-line treatment for advanced or metastatic biliary tract cancer: A double-blind, randomized phase 2 trial","volume":"27","author":"Valle","year":"2016","journal-title":"Ann Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2018-0044","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2018-0044","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/23\/12\/1407\/41915081\/oncolo_23_12_1407.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/23\/12\/1407\/41915081\/oncolo_23_12_1407.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T05:58:58Z","timestamp":1720331938000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/23\/12\/1407\/6439861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,31]]},"references-count":36,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2018,5,31]]},"published-print":{"date-parts":[[2018,12,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2018-0044","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,12,1]]},"published":{"date-parts":[[2018,5,31]]}}}